Neurocrine Partners With Dainippon To Market Indiplon In Japan
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo will market Neurocrine Biosciences' insomnia agent indiplon in Japan under an exclusive liensing agreement announced Nov. 1